Skip to main content

Traversa Sergio's Form 4 filing

Relmada Therapeutics, Inc.RLMD · filed Aug 28, 2025

Accession no.
0001213900-25-081837
Filed
Aug 28, 2025
Trade date
Aug 26-28, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions. Open-market purchases total $178.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Traversa SergioCIK 0001565832Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 26, 2025Common StockPPurchaseAcquired+80,545$0.62F2+$49,937.9814,569Direct
Aug 27, 2025Common StockPPurchaseAcquired+129,455$0.67F3+$86,734.85944,024Direct
Aug 28, 2025Common StockPPurchaseAcquired+55,976$0.74F4+$41,422.241,000,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Purchase prices range from $0.61 to $0.65 per share, inclusive.

Referenced by the price of 1 transaction in Table I.

F3

Purchase prices range from $0.65 to $0.69 per share, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

Purchase prices range from $0.68 to $0.79 per share, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)